Business
Replacement - Director/PDMR Shareholding
Replacement - Director/PDMR Shareholding.
About this update from Gsk Plc
[{"type":"text","content":"\n\nGSK plc (the 'Company')\n \nThe following amendment has been made to the Director/PDMR Shareholding announcement released on 23 June 2025 at 15.30 under RNS No 0150O.\n \n1,350 Ordinary Shares were purchased by Lady Susan Symonds, PCA of Sir Jonathan Symonds (Non-Executive Chair).\n \nAll other details remain unchanged.\n \nThe full amended text is shown below.\n \nGSK plc (the 'Company')\n\nTransaction notification\n\n\n\n\n\n1.\n\n\nDetails of PDMR/person closely associated with them ('PCA')\n\n\n\n\na)\n\n\nName\n\n\nLady Susan Symonds\n\n\n\n\nb)\n\n\nPosition/status\n\n\nPCA of Sir Jonathan Symonds (Non-Executive Chair)\n\n\n\n\nc)\n\n\nInitial notification/\namendment\n\n\nInitial notification\n\n\n\n\n2.\n\n\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\n\n\n\n\na)\n\n\nName\n\n\nGSK plc\n\n\n\n\nb)\n\n\nLEI\n\n\n5493000HZTVUYLO1D793\n\n\n\n\n3.\n\n\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted\n\n\n\n\na)\n\n\nDescription of the financial instrument\n\n\nOrdinary shares of 31 ¼ pence each ('Ordinary Shares')\nISIN: GB00BN7SWP63\n\n\n\n\nb)\n\n\nNature of the transaction\n\n\nPurchase of 1,350 Ordinary Shares\n\n\n\n\nc)\n\n\nPrice(s) and volume(s)\n\n\n\n\n\nPrice(s)\n\n\nVolume(s)\n\n\n\n\n\n\n\n\n\n\n£14.3550\n\n\n1,350\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nd)\n\n\nAggregated information\n \n\n\nN/A (single transaction)\n\n\n\n\nAggregated volume Price\n\n\n\n\n\n\n\ne)\n\n\nDate of the transaction\n\n\n2025-06-20\n\n\n\n\nf)\n\n\nPlace of the transaction\n \n\n\nLondon Stock Exchange (XLON)\n\n\n\n\n \n\n\n\n\n1.\n\n\nDetails of PDMR/person closely associated with them ('PCA')\n\n\n\n\na)\n\n\nName\n\n\nWendy Becker\n\n\n\n\nb)\n\n\nPosition/status\n\n\nIndependent Non-Executive Director\n\n\n\n\nc)\n\n\nInitial notification/\namendment\n\n\nInitial notification\n\n\n\n\n2.\n\n\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\n\n\n\n\na)\n\n\nName\n\n\nGSK plc\n\n\n\n\nb)\n\n\nLEI\n\n\n5493000HZTVUYLO1D793\n\n\n\n\n3.\n\n\nDetails of the transaction(s): section to be repeated for (i) each type of i...